Additional file 1 of Sodium-glucose cotransporter 2 inhibitors, inflammation, and heart failure: a two-sample Mendelian randomization study

Additional file1: Table S1. Detailed information for genome-wide association studies involved in the present Mendelian randomization study. Table S2. Instrumental variables for SGLT2 inhibition. Table S3. Mendelian Randomization analysis on the causal effect between SGLT-2 inhibitor and inflammatory biomarkers. Table S4. Mendelian Randomization analysis on the causal effect between inflammatory biomarkers and heart failure. Table S5. Ranking of models for heart failure according to their posterior probability after exclusion of outlying and influential variants in MR-BMA analysis. Table S6. Characteristics of participating studies.补充材料1：表S1. 本孟德尔随机化研究所涉及的全基因组关联研究详细信息。表S2. 钠-葡萄糖协同转运蛋白2抑制剂（SGLT2 inhibitor）的工具变量。表S3. 钠-葡萄糖协同转运蛋白2抑制剂与炎症生物标志物之间因果效应的孟德尔随机化分析。表S4. 炎症生物标志物与心力衰竭之间因果效应的孟德尔随机化分析。表S5. 在MR-BMA分析中排除异常且有影响力的变异后，基于后验概率对心力衰竭相关模型进行的排序。表S6. 纳入研究的特征。